Antonio Moreno-Flores, María Domínguez-Landesa, María Guadalupe Vázquez-López, Laura Sante-Fernández
Objectives: Ureaplasma species are the most frequently isolated microorganisms in cases of spontaneous preterm labor, premature rupture of the membranes, or chorioamnionitis.
Case presentation: A woman at 28+6 weeks of gestation with no apparent history of interest presented at the hospital with contractions. Upon suspicion of chorioamnionitis, the patient was admitted for a low segment transverse cesarean section, which was completed without any complications. The patient was discharged at 7 days. The newborn remained stable and showed no clinical signs of infection. However, on suspicion of chorioamnionitis, empirical treatment with intravenous ampicillin (2 g every 6 h) and gentamicin (5 mg/kg once daily) was initiated. Samples of pharyngeal/tonsillar, ear, and anal/rectal exudates were collected. At 24 h, all samples were positive for Ureaplasma parvum. Empirical treatment was suspended, and treatment with intravenous azithromycin was initiated (12 mg once daily). Endocervical and placental exudates were also positive for U. parvum. Fifty-two days after birth, the newborn was discharged.
Conclusions: The relationship between Ureaplasma spp. colonization and perinatal disease seem to be clear. However, the high frequency of vaginal Ureaplasma spp. colonization and high rates of term labor among pregnant women with this colonization make further studies necessary.
{"title":"Chorioamnionitis secondary to <i>Ureaplasma parvum</i> infection: a case report.","authors":"Antonio Moreno-Flores, María Domínguez-Landesa, María Guadalupe Vázquez-López, Laura Sante-Fernández","doi":"10.1515/almed-2023-0004","DOIUrl":"https://doi.org/10.1515/almed-2023-0004","url":null,"abstract":"<p><strong>Objectives: </strong><i>Ureaplasma</i> species are the most frequently isolated microorganisms in cases of spontaneous preterm labor, premature rupture of the membranes, or chorioamnionitis.</p><p><strong>Case presentation: </strong>A woman at 28<sup>+6</sup> weeks of gestation with no apparent history of interest presented at the hospital with contractions. Upon suspicion of chorioamnionitis, the patient was admitted for a low segment transverse cesarean section, which was completed without any complications. The patient was discharged at 7 days. The newborn remained stable and showed no clinical signs of infection. However, on suspicion of chorioamnionitis, empirical treatment with intravenous ampicillin (2 g every 6 h) and gentamicin (5 mg/kg once daily) was initiated. Samples of pharyngeal/tonsillar, ear, and anal/rectal exudates were collected. At 24 h, all samples were positive for <i>Ureaplasma parvum</i>. Empirical treatment was suspended, and treatment with intravenous azithromycin was initiated (12 mg once daily). Endocervical and placental exudates were also positive for <i>U. parvum</i>. Fifty-two days after birth, the newborn was discharged.</p><p><strong>Conclusions: </strong>The relationship between <i>Ureaplasma</i> spp. colonization and perinatal disease seem to be clear. However, the high frequency of vaginal <i>Ureaplasma</i> spp<i>.</i> colonization and high rates of term labor among pregnant women with this colonization make further studies necessary.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 1","pages":"128-132"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9717718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cristina Montero Domínguez, Alicia Ortiz Temprado, Laura Martínez Figueras, Alba Guillamón Seoane, Miguel Fernández Ruano
Objectives: The incidence of congenital neuroblastoma has increased in the recent years. The purpose of this study was to describe the clinical and biochemical characteristics of cases of congenital neuroblastoma diagnosed in our center.
Case presentation: We report three cases of congenital neuroblastoma diagnosed in our hospital. In two, diagnosis was made prenatally, whereas the other case was detected in the immediate neonatal period. In the three cases, neuroblastoma was located in the abdominal region and exhibited elevated concentrations of catecholamines or their metabolites in single voided urine samples. Two tumors were classified as stage M, and one as stage L2. The N-MYC oncogen was not amplified in any of the cases studied. Histopathological analysis was favorable in the three cases. The tumor was resected in two patients. The three received chemotherapy.
Conclusions: The measurement of catecholamines and their metabolites is essential in the diagnosis of neuroblastoma. When 24 h urine cannot be collected, single voided urine can be used to calculate the index based on creatinine concentrations.
{"title":"Biochemical analysis in congenital neuroblastoma.","authors":"Cristina Montero Domínguez, Alicia Ortiz Temprado, Laura Martínez Figueras, Alba Guillamón Seoane, Miguel Fernández Ruano","doi":"10.1515/almed-2022-0112","DOIUrl":"https://doi.org/10.1515/almed-2022-0112","url":null,"abstract":"<p><strong>Objectives: </strong>The incidence of congenital neuroblastoma has increased in the recent years. The purpose of this study was to describe the clinical and biochemical characteristics of cases of congenital neuroblastoma diagnosed in our center.</p><p><strong>Case presentation: </strong>We report three cases of congenital neuroblastoma diagnosed in our hospital. In two, diagnosis was made prenatally, whereas the other case was detected in the immediate neonatal period. In the three cases, neuroblastoma was located in the abdominal region and exhibited elevated concentrations of catecholamines or their metabolites in single voided urine samples. Two tumors were classified as stage M, and one as stage L2. The <i>N-MYC</i> oncogen was not amplified in any of the cases studied. Histopathological analysis was favorable in the three cases. The tumor was resected in two patients. The three received chemotherapy.</p><p><strong>Conclusions: </strong>The measurement of catecholamines and their metabolites is essential in the diagnosis of neuroblastoma. When 24 h urine cannot be collected, single voided urine can be used to calculate the index based on creatinine concentrations.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 1","pages":"120-127"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10073183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Acute myeloid leukemia (AML) is a highly heterogeneous disease. Although patients can be classified into risk groups based on their genetic changes, the prognosis of disease within these categories varies widely. This situation raises the need to search for new molecular markers related to AML. Serine peptidase inhibitor Kazal type 2 (SPINK2) has recently been reported to be upregulated in AML and associated with poor outcomes by meta-analysis and in a limited number of AML patients.
Methods: We analyzed SPINK2 mRNA expression in 62 patients (45 adult and 17 pediatric) with AML and 11 cell lines using quantitative Real-Time PCR (qRT-PCR). SPINK2 protein level was determined using ELISA in cell lines.
Results: We found that the expression of SPINK2 mRNA and protein levels in AML cell lines (HL60 and NB4) have increased compared to other cell lines (K562, Jurkat and NALM6, MCF7, HeLa, HUVEC, hFOB, 293T, U87). SPINK2 mRNA expression was upregulated in patients with AML compared to controls (p=0.004) and significantly lower in t(8;21)-positive patients compared to negative patients (p=0.0006).
Conclusions: Our results suggest that SPINK2 serves an important role in AML development. Further studies are needed to evaluate SPINK2 expression in AML patients with t(8.21) and investigate to clarify its prognostic value in various subgroups of AML.
{"title":"Upregulation of SPINK2 in acute myeloid leukemia.","authors":"Sümbül Gezer, Zeliha Emrence, Tuğrul Elverdi, Muhlis Cem Ar, Burcu Salman Yaylaz, Ferda Paçal, Ayşegül Ünüvar, Melda Sarıman, Ahmet Emre Eşkazan, Serap Karaman, Ayşe Salihoğlu, Zeynep Karakaş, Neslihan Abacı, Sema Sırma-Ekmekci","doi":"10.1515/almed-2022-0047","DOIUrl":"https://doi.org/10.1515/almed-2022-0047","url":null,"abstract":"<p><strong>Objectives: </strong>Acute myeloid leukemia (AML) is a highly heterogeneous disease. Although patients can be classified into risk groups based on their genetic changes, the prognosis of disease within these categories varies widely. This situation raises the need to search for new molecular markers related to AML. Serine peptidase inhibitor Kazal type 2 (<i>SPINK2</i>) has recently been reported to be upregulated in AML and associated with poor outcomes by meta-analysis and in a limited number of AML patients.</p><p><strong>Methods: </strong>We analyzed <i>SPINK2</i> mRNA expression in 62 patients (45 adult and 17 pediatric) with AML and 11 cell lines using quantitative Real-Time PCR (qRT-PCR). SPINK2 protein level was determined using ELISA in cell lines.</p><p><strong>Results: </strong>We found that the expression of <i>SPINK2</i> mRNA and protein levels in AML cell lines (HL60 and NB4) have increased compared to other cell lines (K562, Jurkat and NALM6, MCF7, HeLa, HUVEC, hFOB, 293T, U87). <i>SPINK2</i> mRNA expression was upregulated in patients with AML compared to controls (p=0.004) and significantly lower in t(8;21)-positive patients compared to negative patients (p=0.0006).</p><p><strong>Conclusions: </strong>Our results suggest that <i>SPINK2</i> serves an important role in AML development. Further studies are needed to evaluate SPINK2 expression in AML patients with t(8.21) and investigate to clarify its prognostic value in various subgroups of AML.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 1","pages":"92-104"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9769339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-24eCollection Date: 2023-04-01DOI: 10.1515/almed-2023-0024
Carmen Prior-de Castro, Clara Gómez-González, Raquel Rodríguez-López, Hada C Macher
Prenatal genetic diagnosis of monogenic diseases is a process involving the use of a variety of molecular techniques for the molecular characterization of a potential monogenic disease in the fetus during pregnancy. Prenatal genetic diagnosis can be performed through invasive and non-invasive methods. A distinction must be made between "NIPD" (non-invasive prenatal diagnosis), which is considered to be diagnostic, from "NIPT" (non-invasive prenatal test), which is a screening test that requires subsequent confirmation by invasive methods. The different techniques currently available aim at detecting either, previously characterized pathogenic mutations in the family, the risk haplotype associated with the familial mutation, or potential pathogenic mutation(s) in a gene associated with a diagnostic suspicion. An overview is provided of relevant aspects of prenatal genetic diagnosis of monogenic diseases. The objective of this paper is to describe the main molecular techniques currently available and used in clinical practice. A description is provided of the indications, limitations and analytical recommendations regarding these techniques, and the standards governing genetic counseling. Continuous rapid advances in the clinical applications of genomics have provided increased access to comprehensive molecular characterization. Laboratories are struggling to keep in pace with technology developments.
{"title":"Prenatal genetic diagnosis of monogenic diseases.","authors":"Carmen Prior-de Castro, Clara Gómez-González, Raquel Rodríguez-López, Hada C Macher","doi":"10.1515/almed-2023-0024","DOIUrl":"10.1515/almed-2023-0024","url":null,"abstract":"<p><p>Prenatal genetic diagnosis of monogenic diseases is a process involving the use of a variety of molecular techniques for the molecular characterization of a potential monogenic disease in the fetus during pregnancy. Prenatal genetic diagnosis can be performed through invasive and non-invasive methods. A distinction must be made between \"NIPD\" (non-invasive prenatal diagnosis), which is considered to be diagnostic, from \"NIPT\" (non-invasive prenatal test), which is a screening test that requires subsequent confirmation by invasive methods. The different techniques currently available aim at detecting either, previously characterized pathogenic mutations in the family, the risk haplotype associated with the familial mutation, or potential pathogenic mutation(s) in a gene associated with a diagnostic suspicion. An overview is provided of relevant aspects of prenatal genetic diagnosis of monogenic diseases. The objective of this paper is to describe the main molecular techniques currently available and used in clinical practice. A description is provided of the indications, limitations and analytical recommendations regarding these techniques, and the standards governing genetic counseling. Continuous rapid advances in the clinical applications of genomics have provided increased access to comprehensive molecular characterization. Laboratories are struggling to keep in pace with technology developments.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 1","pages":"28-51"},"PeriodicalIF":1.1,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9768885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-24eCollection Date: 2023-06-01DOI: 10.1515/almed-2023-0008
Giuseppe Lippi, Brandon M Henry, Laura Pighi, Simone De Nitto, Gian Luca Salvagno
Objectives: We planned this study to verify whether immunoassays for quantifying anti-SARS-CoV-2 IgG/IgM antibodies against both spike (S) and nucleocapsid (N) proteins may be used for identifying previous SARS-CoV-2 infections.
Methods: The study population consisted of a cohort of fully vaccinated healthcare workers. All study subjects underwent regular medical visits and molecular testing for diagnosing SARS-CoV-2 infections every 2-4 weeks between 2020-2022. Venous blood was drawn for measuring anti-SARS-CoV-2 antibodies with MAGLUMI 2019-nCoV lgG/IgM CLIA Assays directed against both SARS-CoV-2 S and N proteins.
Results: Overall, 31/53 (58.5%) subjects had tested positive for SARS-CoV-2 by RT-PCR throughout the study (24 once, 7 twice). No positive correlation was found between anti-SARS-CoV-2 S/N IgM antibodies and molecular test positivity. In univariate regression analysis, both a molecular test positivity (r=0.33; p=0.015) and the number of positive molecular tests (r=0.43; p=0.001), but not vaccine doses (r=-0.12; p=0.392), were significantly correlated with anti-SARS-CoV-2 S/N IgG antibodies. These two associations remained significant in multiple linear regression analysis (p=0.029 and p<0.001, respectively) after adjusting for sex, age, body mass index, and vaccine doses. In ROC curve analysis, anti-SARS-CoV-2 S/N IgG antibodies significantly predicted molecular test positivity (AUC, 0.69; 95% CI; 0.55-0.84), with the best cutoff of 0.05 AU/mL displaying 67.9% accuracy, 0.97 sensitivity, and 0.27 specificity.
Conclusions: Although anti-SARS-CoV-2 S/N IgG antibodies provide helpful information for identifying previous SARS-CoV-2 infections, a lower cutoff than that of sample reactivity should be used. Anti-SARS-CoV-2 S/N IgM antibodies using conventional cutoffs seem useless for this purpose.
{"title":"Are anti-SARS-CoV-2 S/N IgG/IgM antibodies always predictive of previous SARS-CoV-2 infection?","authors":"Giuseppe Lippi, Brandon M Henry, Laura Pighi, Simone De Nitto, Gian Luca Salvagno","doi":"10.1515/almed-2023-0008","DOIUrl":"10.1515/almed-2023-0008","url":null,"abstract":"<p><strong>Objectives: </strong>We planned this study to verify whether immunoassays for quantifying anti-SARS-CoV-2 IgG/IgM antibodies against both spike (S) and nucleocapsid (N) proteins may be used for identifying previous SARS-CoV-2 infections.</p><p><strong>Methods: </strong>The study population consisted of a cohort of fully vaccinated healthcare workers. All study subjects underwent regular medical visits and molecular testing for diagnosing SARS-CoV-2 infections every 2-4 weeks between 2020-2022. Venous blood was drawn for measuring anti-SARS-CoV-2 antibodies with MAGLUMI 2019-nCoV lgG/IgM CLIA Assays directed against both SARS-CoV-2 S and N proteins.</p><p><strong>Results: </strong>Overall, 31/53 (58.5%) subjects had tested positive for SARS-CoV-2 by RT-PCR throughout the study (24 once, 7 twice). No positive correlation was found between anti-SARS-CoV-2 S/N IgM antibodies and molecular test positivity. In univariate regression analysis, both a molecular test positivity (r=0.33; p=0.015) and the number of positive molecular tests (r=0.43; p=0.001), but not vaccine doses (r=-0.12; p=0.392), were significantly correlated with anti-SARS-CoV-2 S/N IgG antibodies. These two associations remained significant in multiple linear regression analysis (p=0.029 and p<0.001, respectively) after adjusting for sex, age, body mass index, and vaccine doses. In ROC curve analysis, anti-SARS-CoV-2 S/N IgG antibodies significantly predicted molecular test positivity (AUC, 0.69; 95% CI; 0.55-0.84), with the best cutoff of 0.05 AU/mL displaying 67.9% accuracy, 0.97 sensitivity, and 0.27 specificity.</p><p><strong>Conclusions: </strong>Although anti-SARS-CoV-2 S/N IgG antibodies provide helpful information for identifying previous SARS-CoV-2 infections, a lower cutoff than that of sample reactivity should be used. Anti-SARS-CoV-2 S/N IgM antibodies using conventional cutoffs seem useless for this purpose.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 1","pages":"175-184"},"PeriodicalIF":0.0,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10701493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43514980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniel Bravo Nieto, Alba S. García Fernández, Noelia Diaz Troyano, Marina Giralt Arnaiz, Andrea Arias García, Paula Fernández Álvarez, Ariadna Campos Martorell, Roser Ferrer Costa, María Clemente León
Resumen Objetivos La hipoplasia suprarrenal congénita ligada al cromosoma X es una enfermedad rara con base genética conocida, que se presenta con insuficiencia suprarrenal e hipogonadismo hipogonadotrófico y expresión clínica variable. Caso clínico Paciente varón, de 26 días, que ingresó con síntomas compatibles con insuficiencia suprarrenal, hiponatremia e hiperpotasemia, requiriendo sueroterapia con suplementos de NaCl y fludrocortisona, consiguiéndose estabilidad clínica. Se descartó la hiperplasia suprarrenal congénita tras la medición de 17-OH-progesterona. El resto de hormonas estaban dentro de los intervalos de referencia, salvo la hormona adrenocorticotrópica (ACTH), sensiblemente por encima, y la aldosterona, por debajo. En los siguientes análisis se estudiaron los ácidos grasos de cadena muy larga para descartar adrenoleucodistrofia, el gen CYP11B2 (aldosterona sintasa), y se realizó una RMN para descartar otras alteraciones morfológicas. Todas estas pruebas resultaron normales. Finalmente, tras detectar déficit de cortisol en una analítica, se realizó un estudio genético más amplio donde se describió una mutación en el gen NR0B1, estableciéndose el diagnóstico de hipoplasia suprarrenal congénita. Conclusiones La hipoplasia suprarrenal congénita es una enfermedad de diagnóstico complejo debido a la variabilidad en la expresión clínica y el grado de alteración de las pruebas de laboratorio, requiriéndose un seguimiento exhaustivo y la realización de pruebas genéticas para llegar al diagnóstico.
{"title":"Paciente con insuficiencia suprarrenal por mutación de novo en el gen NR0B1","authors":"Daniel Bravo Nieto, Alba S. García Fernández, Noelia Diaz Troyano, Marina Giralt Arnaiz, Andrea Arias García, Paula Fernández Álvarez, Ariadna Campos Martorell, Roser Ferrer Costa, María Clemente León","doi":"10.1515/almed-2022-0099","DOIUrl":"https://doi.org/10.1515/almed-2022-0099","url":null,"abstract":"Resumen Objetivos La hipoplasia suprarrenal congénita ligada al cromosoma X es una enfermedad rara con base genética conocida, que se presenta con insuficiencia suprarrenal e hipogonadismo hipogonadotrófico y expresión clínica variable. Caso clínico Paciente varón, de 26 días, que ingresó con síntomas compatibles con insuficiencia suprarrenal, hiponatremia e hiperpotasemia, requiriendo sueroterapia con suplementos de NaCl y fludrocortisona, consiguiéndose estabilidad clínica. Se descartó la hiperplasia suprarrenal congénita tras la medición de 17-OH-progesterona. El resto de hormonas estaban dentro de los intervalos de referencia, salvo la hormona adrenocorticotrópica (ACTH), sensiblemente por encima, y la aldosterona, por debajo. En los siguientes análisis se estudiaron los ácidos grasos de cadena muy larga para descartar adrenoleucodistrofia, el gen CYP11B2 (aldosterona sintasa), y se realizó una RMN para descartar otras alteraciones morfológicas. Todas estas pruebas resultaron normales. Finalmente, tras detectar déficit de cortisol en una analítica, se realizó un estudio genético más amplio donde se describió una mutación en el gen NR0B1, estableciéndose el diagnóstico de hipoplasia suprarrenal congénita. Conclusiones La hipoplasia suprarrenal congénita es una enfermedad de diagnóstico complejo debido a la variabilidad en la expresión clínica y el grado de alteración de las pruebas de laboratorio, requiriéndose un seguimiento exhaustivo y la realización de pruebas genéticas para llegar al diagnóstico.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 1","pages":"199 - 202"},"PeriodicalIF":0.0,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47060602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-15eCollection Date: 2023-06-01DOI: 10.1515/almed-2023-0018
Daniel Bravo Nieto, Alba S García Fernández, Noelia Díaz Troyano, Marina Giralt Arnaiz, Andrea Arias García, Paula Fernández Álvarez, Ariadna Campos Martorell, Roser Ferrer Costa, María Clemente León
Objectives: Congenital X-linked adrenal hypoplasia is a rare disease with a known genetic basis characterized by adrenal insufficiency, hypogonadotropic hypogonadism, and a wide variety of clinical manifestations.
Case presentation: We present the case of a 26-day old male newborn with symptoms consistent with adrenal insufficiency, hyponatremia, and hyperkalemia. Following NaCl and fludrocortisone supplementation, the patient remained clinically stable. 17-OH-progesterone testing excluded congenital adrenal hyperplasia. The rest of hormones were within normal limits, except for adrenocorticotropic hormone (ACTH), which was significantly elevated, and aldosterone, which was below the reference value. Further testing included very long chain fatty acids to exclude adrenoleukodystrophy, the CYP11B2 gene (aldosterone synthase), and an MRI to screen for other morphological abnormalities. All tests yielded normal results. Finally, after cortisol deficiency was detected, expanded genetic testing revealed a mutation in the NR0B1 gene, which led to a diagnosis of congenital adrenal hypoplasia.
Conclusions: Diagnosis of congenital adrenal hypoplasia is challenging due to the heterogeneity of both clinical manifestations and laboratory abnormalities. As a result, diagnosis requires close monitoring and genetic testing.
{"title":"Patient with adrenal insufficiency due to a <i>de novo</i> mutation in the <i>NR0B1</i> gene.","authors":"Daniel Bravo Nieto, Alba S García Fernández, Noelia Díaz Troyano, Marina Giralt Arnaiz, Andrea Arias García, Paula Fernández Álvarez, Ariadna Campos Martorell, Roser Ferrer Costa, María Clemente León","doi":"10.1515/almed-2023-0018","DOIUrl":"10.1515/almed-2023-0018","url":null,"abstract":"<p><strong>Objectives: </strong>Congenital X-linked adrenal hypoplasia is a rare disease with a known genetic basis characterized by adrenal insufficiency, hypogonadotropic hypogonadism, and a wide variety of clinical manifestations.</p><p><strong>Case presentation: </strong>We present the case of a 26-day old male newborn with symptoms consistent with adrenal insufficiency, hyponatremia, and hyperkalemia. Following NaCl and fludrocortisone supplementation, the patient remained clinically stable. 17-OH-progesterone testing excluded congenital adrenal hyperplasia. The rest of hormones were within normal limits, except for adrenocorticotropic hormone (ACTH), which was significantly elevated, and aldosterone, which was below the reference value. Further testing included very long chain fatty acids to exclude adrenoleukodystrophy, the <i>CYP11B2</i> gene (aldosterone synthase), and an MRI to screen for other morphological abnormalities. All tests yielded normal results. Finally, after cortisol deficiency was detected, expanded genetic testing revealed a mutation in the <i>NR0B1</i> gene, which led to a diagnosis of congenital adrenal hypoplasia.</p><p><strong>Conclusions: </strong>Diagnosis of congenital adrenal hypoplasia is challenging due to the heterogeneity of both clinical manifestations and laboratory abnormalities. As a result, diagnosis requires close monitoring and genetic testing.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 1","pages":"195-202"},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10701479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48859340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-10eCollection Date: 2023-04-01DOI: 10.1515/almed-2023-0022
Joan Lopez Hellin
{"title":"Recommendations for the measurement of sexual steroids. A step forward in the silent revolution of mass spectrometry.","authors":"Joan Lopez Hellin","doi":"10.1515/almed-2023-0022","DOIUrl":"10.1515/almed-2023-0022","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 1","pages":"1-4"},"PeriodicalIF":1.1,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197180/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10091841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Myotonic dystrophy type 1 (DM1), also known as Steinert's disease, is a chronic, progressive and disabling multisystemic disorder with a broad spectrum of severity that arises from an autosomal-dominant expansion of the Cytosine-Thymine-Guanine (CTG) triplet repeat in the 3' untranslated region of the DMPK gene (19q13.3).
Case presentation: In this study, we report the case of a family with several intergenerational expansions of the CTG repeat, with an additional case of a false suspicion of contraction phenomenon due to TP-PCR limitations.
Conclusions: The meiotic instability of the (CTG)n repeats leads to genetic anticipation where increased size of DM1 mutation and a more severe phenotype have been reported in affected individuals across generations. Even if extremely rare, a decrease in the CTG repeat size during transmission from parents to child can also occur, most frequently during paternal transmissions.
{"title":"No increase in the CTG repeat size during transmission from parent with expanded allele: false suspicion of contraction phenomenon.","authors":"Nuria Goñi Ros, Paula Sienes Bailo, Ricardo González Tarancón, Loreto Martorell Sampol, Silvia Izquierdo Álvarez","doi":"10.1515/almed-2022-0079","DOIUrl":"10.1515/almed-2022-0079","url":null,"abstract":"<p><strong>Objectives: </strong>Myotonic dystrophy type 1 (DM1), also known as Steinert's disease, is a chronic, progressive and disabling multisystemic disorder with a broad spectrum of severity that arises from an autosomal-dominant expansion of the Cytosine-Thymine-Guanine (CTG) triplet repeat in the 3' untranslated region of the <i>DMPK</i> gene (19q13.3).</p><p><strong>Case presentation: </strong>In this study, we report the case of a family with several intergenerational expansions of the CTG repeat, with an additional case of a false suspicion of contraction phenomenon due to TP-PCR limitations.</p><p><strong>Conclusions: </strong>The meiotic instability of the (CTG)<sub>n</sub> repeats leads to genetic anticipation where increased size of DM1 mutation and a more severe phenotype have been reported in affected individuals across generations. Even if extremely rare, a decrease in the CTG repeat size during transmission from parents to child can also occur, most frequently during paternal transmissions.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 1","pages":"185-194"},"PeriodicalIF":0.0,"publicationDate":"2023-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10701496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45146267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nuria Goñi Ros, P. Sienes Bailo, Ricardo González Tarancón, Loreto Martorell Sampol, S. Izquierdo Álvarez
Resumen Objetivos La distrofia miotónica tipo 1, conocida también como enfermedad de Steinert, es un desorden multisistémico crónico, degenerativo e incapacitante de expresividad clínica muy variable provocado por una expansión heredada de manera autosómica dominante de la repetición del triplete citosina-timina-guanina, localizada en la región 3′ no codificante del gen DMPK (19q13.3). Caso clínico En este estudio, presentamos el caso de una familia con varias expansiones de la repetición CTG intergeneracionales, con un caso adicional de falsa sospecha de fenómeno de contracción, debido a las limitaciones de la técnica TP-PCR. Conclusiones La inestabilidad meiótica de las repeticiones de (CTG)n provoca anticipación genética. De este modo, a lo largo de las sucesivas generaciones, se ha hallado un incremento del tamaño de la mutación DM1 y un fenotipo más severo en los individuos afectados. Aunque es extremadamente infrecuente, en la transmisión de padres a hijos, también puede producirse una disminución en el número de repeticiones CTG, siendo esta más frecuente en la transmisión paterna.
{"title":"Tamaño de repeticiones CTG no aumentado en la transmisión de un padre con alelo expandido: falsa sospecha de fenómeno de contracción","authors":"Nuria Goñi Ros, P. Sienes Bailo, Ricardo González Tarancón, Loreto Martorell Sampol, S. Izquierdo Álvarez","doi":"10.1515/almed-2022-0120","DOIUrl":"https://doi.org/10.1515/almed-2022-0120","url":null,"abstract":"Resumen Objetivos La distrofia miotónica tipo 1, conocida también como enfermedad de Steinert, es un desorden multisistémico crónico, degenerativo e incapacitante de expresividad clínica muy variable provocado por una expansión heredada de manera autosómica dominante de la repetición del triplete citosina-timina-guanina, localizada en la región 3′ no codificante del gen DMPK (19q13.3). Caso clínico En este estudio, presentamos el caso de una familia con varias expansiones de la repetición CTG intergeneracionales, con un caso adicional de falsa sospecha de fenómeno de contracción, debido a las limitaciones de la técnica TP-PCR. Conclusiones La inestabilidad meiótica de las repeticiones de (CTG)n provoca anticipación genética. De este modo, a lo largo de las sucesivas generaciones, se ha hallado un incremento del tamaño de la mutación DM1 y un fenotipo más severo en los individuos afectados. Aunque es extremadamente infrecuente, en la transmisión de padres a hijos, también puede producirse una disminución en el número de repeticiones CTG, siendo esta más frecuente en la transmisión paterna.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 1","pages":"190 - 194"},"PeriodicalIF":0.0,"publicationDate":"2023-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47827037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}